




FIG. 1A




FIG. 1B




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 3D




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D




FIG. 4E





FIG. 4F



Species	EC ₅₀ (µg/ml)		
	B cells	CD8+ T cells	CD4+ T cells
Human	0.375±0.046	44.19±5.082	7.93±0.92
Cynomolgus monkey	1.72±0.79	28.66±1.21	28.86±4.31
Mouse	>100	>100	>100

FIG. 5B

Species	Protein	Serum Albumin	ka (1/Ms)	KD (nM)
Human	CD19	-	1.90 x 10 ⁵	0.0738
		+	ND	ND*
	CD3	-	6.98 x 10 ³	7.18
		+	2.23 x 10 ⁵	16.79
Cynomolgus	CD19	-	9.26 x 10 ⁴	19.22
		+	3.08 x 10 ⁴	44.98
	CD3	-	7.30 x10 ³	6.04
		+	2.05 x 10 ³	16.45
*The kinetics of CLN-978 were not amenable to the investigation of the effects of albumin on the CLN-978-human CD19 interaction				

FIG. 6




FIG. 7A




FIG. 7B




FIG. 7C





FIG. 7D







FIG. 8A




Data represents mean with $\pm$ SD (n=10 for Ramos assessments, n=8 for Raji assessments)

Albumin Treatment	Target Cell	EC ₅₀ (pM)	SEM
Y	Ramos	29.97	5.01
	Raji	9.30	2.06
N	Ramos	1.73	0.27
	Raji	0.34*	0.11

* Software was capable of calculating a best-fit value, however, was unable to calculate a complete confidence interval, therefore, the determined EC₅₀ should be interpreted with caution.

FIG. 8B



Data represents mean with $\pm$ SD (n=10 for Ramos assessments, n=8 for Raji assessments)

Albumin treatment	Target Cell Line	CD4+CD25+		CD4+CD69+		CD8+CD25+		CD8+CD69+	
		EC ₅₀ (pM)	SEM	EC ₅₀ (pM)	SEM	EC ₅₀ (pM)	SEM	EC ₅₀ (pM)	SEM
Y	Ramos	15.76	1.97	3.03	0.26	11.62	0.88	2.12	0.25
	Raji	3.38	0.55	1.43	0.21	4.10	0.73	1.02	0.17
N	Ramos	1.48	0.29	0.19	0.26	1.10	0.21	0.15	0.03
	Raji	0.23	0.07	0.03	0.03	0.33	0.10	0.02	0.03

FIG. 8C




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D




FIG. 9E




FIG. 10A




FIG. 10B





FIG. 10C






FIG. 11B





FIG. 12A

Analyte	Dose (µg/kg)	Route of Administration	C _{max} (ng/mL)	T _{max} (hr)	T _{1/2α} (hr)
CLN-978	3	IV	11.9	0.25	4 ^a
CLN-978	30	IV	126.4	0.25	72
CLN-978	30	SC	16.7	24	72

^a Note, two of four samples at 4 hours post dose were BQL (6.95 ng/mL).

FIG. 12B



Sample	T=0d	T=7d	T=14d
EC ₅₀	0.038 ng/mL	0.046 ng/mL	0.052 ng/mL

FIG. 13

Group No.	Test Material	Dose Level (mg/kg)	Dose Volume ² (mL/kg)	Dose Concentration (mg/mL)	Route of Administration	No. ^b of Females
1	CLN-973	0.1	1	0.1	IV ^c	2
2		1	1	1	IV	2
3		0.1	0.5	0.2	SC ^d	2
4		1	0.5	2*	SC	2

² Based on the most recent body weight measurement.
^b No. = Number
^c IV = Intravenous injection
^d SC = Subcutaneous injection
* Rounded dose concentration as per Certificate of Testing

FIG. 14A




FIG. 14B




FIG. 14C




FIG. 14D




FIG. 14E




FIG. 15A




FIG. 15B




FIG. 15C




FIG. 15D

Group	Treatment	Dose (mg/kg)	Subject	C _{max} (ng/mL)	C ₀ (ng/mL)	T _{max} (hr)	T _{1/2} (hr)	AUC _{0-∞} (hr*ng/mL)	AUC _{0-t} (hr*ng/mL)	Cl (mL/hr/kg)	V _s (mL/kg)	
1	IV	100000	1501	1920	2080	0.250	144	43.3	60500	69100	1.45	86.6
			1502	1710	1730	0.250	312	113	95100	109000	0.920	116
			Mean	1820	1900	0.250	228	78.2	77800	89900	1.18	101
			SD	152	247	0.00	119	48.6	24500	28000	0.373	21.0
			CV%	8.36	12.9	0.00	52.1	62.2	31.5	31.5	31.5	20.7
2	IV	1000000	2501	21200	22300	0.250	6.00	ND*	ND*	ND*	ND*	
			2502	18800	19800	0.250	672	98.3	1430000	0.697	98.0	
			Mean	20000	21000	0.250	339	98.3	758000	1430000	0.697	98.0
			SD	1730	1710	0.00	471	NA	939000	NA	NA	NA
			CV%	8.64	8.14	0.00	139	NA	124	NA	NA	NA

* no parameters could be calculated, because the following criteria were not met in order to accept a $t_{1/2}$ estimate and to report $t_{1/2}$, $t_{1/2\alpha}$, or $AUC_{0-\infty}$: (1) three or more points in the terminal phase (C_{max} could not be included); (2) adjusted R² (goodness of fit statistic for the terminal phase adjusted for number of points used) > 0.85; (3) %AUC_{0-∞} (the percentage of AUC_{0-∞} that is due to extrapolation from C_{last} to infinity) < 10%; and (4) $t_{1/2}$ less than one-half the time interval over which $t_{1/2}$ was estimated

AUC_{0-∞}: area under the concentration versus time curve from time zero to infinity; AUC_{0-t}: area under the concentration versus time curve from time zero to the time of the last measurable concentration; C_{max}: maximum concentration; C_{last}: time of the last measurable concentration; T_{max}: time of occurrence of maximum concentration; $t_{1/2}$: the apparent terminal half-life; V_d: the steady state volume of distribution; NA: not applicable; ND: could not be determined.

FIG. 16A

Group	Treatment	Dose (mg/kg)	Subject	C _{max} (ng/mL)	T _{max} (hr)	T _{1/2} (hr)	T _{1/2} (hr)	AUC _{0-∞} (hr•ng/mL)	AUC _{0-∞} (hr•ng/mL)
3	SC	1000000	3501	424	24.0	312	ND ^a	92700	ND ^a
			3502	453	144	312	ND ^a	95600	ND ^a
			Mean	439	64.0	312	NA	94100	NA
			SD	21.0	84.0	0.00	NA	2020	NA
4	SC	1000000	CV%	4.79	101	0.00	NA	2.14	NA
			4501	3710	144	672	167	133000	143000
			4502	3360	24.0	672	110	93300	96000
			Mean	3540	84.0	672	138	113000	120000
			SD	241	64.0	0.00	40.3	17900	33000
			CV%	6.82	101	0.00	29.1	24.7	27.8

^a no parameters could be calculated, because the following criteria were not met in order to select a λ_z estimate and to report λ_z , t_{1/2}, or AUC_{0-∞}: (1) three or more points in the terminal phase (C_{max} could not be included); (2) adjusted R² (goodness of fit statistic for the terminal phase adjusted for number of points used) > 0.83; (3) %AUC_{0-∞} (the percentage of AUC_{0-∞} that is due to extrapolation from C_{max} to infinity) < 20%; and (4) t_{1/2} less than one-half the time interval over which λ_z was estimated. AUC_{0-∞} area under the concentration versus time curve from time zero to infinity; AUC_{0-t} area under the concentration versus time curve from time zero to the time of the last measurable concentration; C_{max} maximum concentration; t_{max} time of the last measurable concentration; T_{max} time of occurrence of maximum concentration; t_{1/2} the apparent terminal half-life; V_d the steady state volume of distribution; NA: not applicable; ND: could not be determined

FIG. 16B




FIG. 17




FIG. 18A




FIG. 18B




FIG. 19




FIG. 20




FIG. 21A




FIG. 21B




FIG. 21C




FIG. 21D




FIG. 21E







FIG. 21F



Disease Characteristics and Efficacy Observations					Treatment Emergent Adverse Events				
ID	Diagnosis	Prior Lines	Duration of CLN-978 Treatment	Best Response*	Worst Grade Non-Hematological	Worst Grade Hematological	Worst Grade CRS	Worst Grade ICANS	
1	DLBCL	3	9 doses (off treatment)	PD	Gr 1 fatigue, nausea, headache	Gr 4 lymphopenia†	Gr 1 (fever)	None	
2	Follicular	3	24 doses (ongoing)	SD	Gr 1 hypocalcemia, hyponatremia	Gr 4 lymphopenia	Gr 1 (fever)	None	
3	Mantle	3	7 doses (off treatment)	PR	Gr 3 vascular access complication (DVT)†	Gr 3 lymphopenia	None	None	

• All patients treated at starting dose: 30 ug SC QW

• 2 of 3 patients demonstrated objective clinical benefit

• Class toxicity: max Gr 1 CRS, no ICANS

• Other adverse events: low-grade, manageable, mechanistically based (e.g. lymphopenia), or unrelated

FIG. 23




FIG. 24